WO2025067231 - GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS
National phase entry:
Publication Number
WO/2025/067231
Publication Date
03.04.2025
International Application No.
PCT/CN2024/121081
International Filing Date
25.09.2024
Title **
[English]
GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS
[French]
ANIMAUX NON HUMAINS GÉNÉTIQUEMENT MODIFIÉS AYANT UN LOCUS D'IMMUNOGLOBULINE HUMANISÉE
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Inventors
ZHANG, Lijun
ZHANG, Yabo
HU, Yiqing
ZHAO, Huizhen
YAO, Jiawei
Priority Data
PCT/CN2023/121356
26.09.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3741 | |
| EPO | Filing, Examination, Granting | 46939 | |
| Japan | Filing, Examination, Granting | 3650 | |
| South Korea | Filing, Examination, Granting | 5052 | |
| USA | Filing, Examination, Granting | 19390 |
Total:
78,772
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Genetically modified animals and cells with a humanized lambda light chain immunoglobulin locus and/or a humanized heavy chain immunoglobulin locus are provided. Genetically modified animals and cells with a modified locus containing human lambda light chain immunoglobulin genes and/or a humanized heavy chain immunoglobulin locus are also provided. In some embodiments, the animals further have a humanized kappa light chain immunoglobulin locus.[French]
L'invention concerne des animaux et des cellules génétiquement modifiés avec un locus d'immunoglobuline à chaîne légère lambda humanisé et/ou un locus d'immunoglobuline à chaîne lourde humanisé. L'invention concerne également des animaux et des cellules génétiquement modifiés avec un locus modifié contenant des gènes d'immunoglobuline de chaîne légère lambda humaine et/ou un locus d'immunoglobuline de chaîne lourde humanisé. Dans certains modes de réalisation, les animaux ont en outre un locus d'immunoglobuline à chaîne légère kappa humanisé.